Mercer Global Advisors
CELG.RT

Mercer Global Advisors’s Bristol-Myers Squibb Rights CELG.RT Stock Holding History

Mercer Global Advisors’s Portfolio CELG.RT Stock Details CELG.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11 Buy
+125
New +$13 ﹤0.01% 6055

Other funds holding CELG.RT

TCA
Transcend Capital Advisors Madison, New Jersey $1.48B AUM 25.55% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
PCA
Purkiss Capital Advisors Ridgefield, Connecticut $263M AUM 29.59% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return
RIL
Rothschild Investment LLC Chicago, Illinois $2.68B AUM 34.39% 1-Year Est. Return
OC
Oakworth Capital Birmingham, Alabama $2.1B AUM 24.07% 1-Year Est. Return
AEPWM
Atlantic Edge Private Wealth Management Jacksonville, Florida $489M AUM 33.02% 1-Year Est. Return

Mercer Global Advisors's CELG.RT Position: Q2 2026 in Review

Mercer Global Advisors opened a new position in Bristol-Myers Squibb Rights (CELG.RT) in Q2 2026: 125 shares worth $11. The stake represents ﹤0.01% of the portfolio and ranks #6055 among its holdings.

9 funds tracked by Wall St. Rank hold CELG.RT as of Q2 2026.

  • Mercer Global Advisors held 125 shares of Bristol-Myers Squibb Rights worth $11 as of Q2 2026.
  • Bristol-Myers Squibb Rights was a new Mercer Global Advisors position in Q2 2026.
  • Bristol-Myers Squibb Rights made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #6055 holding.
  • 9 funds tracked by Wall St. Rank held Bristol-Myers Squibb Rights as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.